Atezolizumab Plus nab-Paclitaxel in the Treatment of Metastatic Triple-Negative Breast Cancer With 2-Year Survival Follow-up: A Phase 1b Clinical Trial

IMPORTANCE: The humanized monoclonal antibody atezolizumab targets programmed death-ligand 1 and has demonstrated durable single-agent activity in a subset of metastatic triple-negative breast cancers. To extend the observed activity, combinatorial approaches are being tested with standard cytotoxic...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:JAMA Oncol
Autori principali: Adams, Sylvia, Diamond, Jennifer R., Hamilton, Erika, Pohlmann, Paula R., Tolaney, Sara M., Chang, Ching-Wei, Zhang, Wei, Iizuka, Koho, Foster, Paul G., Molinero, Luciana, Funke, Roel, Powderly, John
Natura: Artigo
Lingua:Inglês
Pubblicazione: American Medical Association 2018
Soggetti:
Original Investigation
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC6439843/
https://ncbi.nlm.nih.gov/pubmed/30347025
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1001/jamaoncol.2018.5152
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi